Biomarkers in GIST: Partly Ready for Prime-Time Use

被引：6

作者：

Blanke, Charles D. ^{[1
,2
]}

机构：

[1] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada

[2] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada

来源：

CLINICAL CANCER RESEARCH | 2009年 / 15卷 / 18期

关键词：

IMATINIB MESYLATE; KIT;

D O I：

10.1158/1078-0432.CCR-09-1563

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Gastrointestinal stromal tumors, or GISTs, are now among the most treatable of solid malignancies. Assessing actual tumor response remains challenging; however, in this issue of Clinical Cancer Research, two articles discuss biomarkers potentially helpful in predicting response or other long-term benefits with standard tyrosine kinase therapy use. (Clin Cancer Res 2009;15(18):5603-5)

引用

页码：5603 / 5605

页数：3

共 6 条

[1] Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT [J].

Blanke, Charles D. ;

Demetri, George D. ;

von Mehren, Margaret ;

Heinrich, Michael C. ;

Eisenberg, Burton ;

Fletcher, Jonathan A. ;

Corless, Christopher L. ;

Fletcher, Christopher D. M. ;

Roberts, Peter J. ;

Heinz, Daniela ;

Wehre, Elisabeth ;

Nikolova, Zariana ;

Joensuu, Heikki .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) :620-625

[2] Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib [J].

Bono, P ;

Krause, A ;

von Mehren, M ;

Heinrich, MC ;

Blanke, CD ;

Dimitrijevic, S ;

Demetri, GD ;

Joensuu, H .

BLOOD, 2004, 103 (08) :2929-2935

[3] Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria [J].

Choi, Haesun ;

Charnsangavej, Chuslip ;

Faria, Silvana C. ;

Macapinlac, Homer A. ;

Burgess, Michael A. ;

Patel, Shreyaskumar R. ;

Chen, Lei L. ;

Podoloff, Donald A. ;

Benjamin, Robert S. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) :1753-1759

[4] Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure [J].

Demetri, George D. ;

Heinrich, Michael C. ;

Fletcher, Jonathan A. ;

Fletcher, Christopher D. M. ;

Van den Abbeele, Annick D. ;

Corless, Christopher L. ;

Antonescu, Cristina R. ;

George, Suzanne ;

Morgan, Jeffrey A. ;

Chen, Ming Hui ;

Bello, Carlo L. ;

Huang, Xin ;

Cohen, Darrel P. ;

Baum, Charles M. ;

Maki, Robert G. .

CLINICAL CANCER RESEARCH, 2009, 15 (18) :5902-5909

[5] Circulating Levels of Soluble KIT Serve as a Biomarker for Clinical Outcome in Gastrointestinal Stromal Tumor Patients Receiving Sunitinib following Imatinib Failure [J].

DePrimo, Samuel E. ;

Huang, Xin ;

Blackstein, Martin E. ;

Garrett, Christopher R. ;

Harmon, Charles S. ;

Schoffski, Patrick ;

Shah, Manisha H. ;

Verweij, Jaap ;

Baum, Charles M. ;

Demetri, George D. .

CLINICAL CANCER RESEARCH, 2009, 15 (18) :5869-5877

[6]

DEPRIMO SE, 2003, P AM ASSOC CANC RES, V44, P678

← 1 →